Alnylam Pharmaceuticals Share Price Weakness Looks 'Overdone' Despite Softer Quarter, RBC Says

MT Newswires Live07-31

Alnylam Pharmaceuticals (ALNY) share price weakness appears overdone despite a softer quarter, with Amvuttra growth and pipeline progress supporting upside, RBC Capital Markets said in a note emailed Friday.

The analysts said Amvuttra revenue came in slightly below expectations, and the company lowered its full-year transthyretin revenue guidance after acknowledging that the early stages of the launch benefited from pent-up demand, particularly from patients who had stopped responding to tafamidis.

The company reaffirmed its goal of delivering more than 25% total revenue compound annual growth rate through 2030, "but our read is that the company sounded a bit more measured on that goal as they referred to it as an ambition more than a formal guide," the analysts said.

The analysts said, overall, the update was disappointing, but the recent share price weakness appears "overdone." The stock now trades at less than 2.5 times guided 2030 revenue, which still offers attractive upside if execution remains strong.

RBC lowered its price target on Alnylam Pharmaceuticals from $445 to $350 and has an outperform rating on the stock.

Price: 205.69, Change: +0.21, Percent Change: +0.10

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2655636030?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-31 23:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2655636030","market":"sh","top_or_hot":-1,"title":"Alnylam Pharmaceuticals Share Price Weakness Looks 'Overdone' Despite Softer Quarter, RBC Says","media":"MT Newswires Live","content":"<html><body><p> Alnylam Pharmaceuticals (ALNY) share price weakness appears overdone despite a softer quarter, with Amvuttra growth and pipeline progress supporting upside, RBC Capital Markets said in a note emailed Friday.</p><p>The analysts said Amvuttra revenue came in slightly below expectations, and the company lowered its full-year transthyretin revenue guidance after acknowledging that the early stages of the launch benefited from pent-up demand, particularly from patients who had stopped responding to tafamidis.</p><p>The company reaffirmed its goal of delivering more than 25% total revenue compound annual growth rate through 2030, \"but our read is that the company sounded a bit more measured on that goal as they referred to it as an ambition more than a formal guide,\" the analysts said.</p><p>The analysts said, overall, the update was disappointing, but the recent share price weakness appears \"overdone.\" The stock now trades at less than 2.5 times guided 2030 revenue, which still offers attractive upside if execution remains strong.</p><p>RBC lowered its price target on Alnylam Pharmaceuticals from $445 to $350 and has an outperform rating on the stock.</p><p>Price: 205.69, Change: +0.21, Percent Change: +0.10</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alnylam Pharmaceuticals Share Price Weakness Looks 'Overdone' Despite Softer Quarter, RBC Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlnylam Pharmaceuticals Share Price Weakness Looks 'Overdone' Despite Softer Quarter, RBC Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-31 23:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Alnylam Pharmaceuticals (ALNY) share price weakness appears overdone despite a softer quarter, with Amvuttra growth and pipeline progress supporting upside, RBC Capital Markets said in a note emailed Friday.</p><p>The analysts said Amvuttra revenue came in slightly below expectations, and the company lowered its full-year transthyretin revenue guidance after acknowledging that the early stages of the launch benefited from pent-up demand, particularly from patients who had stopped responding to tafamidis.</p><p>The company reaffirmed its goal of delivering more than 25% total revenue compound annual growth rate through 2030, \"but our read is that the company sounded a bit more measured on that goal as they referred to it as an ambition more than a formal guide,\" the analysts said.</p><p>The analysts said, overall, the update was disappointing, but the recent share price weakness appears \"overdone.\" The stock now trades at less than 2.5 times guided 2030 revenue, which still offers attractive upside if execution remains strong.</p><p>RBC lowered its price target on Alnylam Pharmaceuticals from $445 to $350 and has an outperform rating on the stock.</p><p>Price: 205.69, Change: +0.21, Percent Change: +0.10</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2655636030","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2655636030","pubTimestamp":1785510196,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Alnylam Pharmaceuticals  share price weakness appears overdone despite a softer quarter, with Amvuttra growth and pipeline progress supporting upside, RBC Capital Markets said in a note emailed Friday.The analysts said Amvuttra revenue came in slightly below expectations, and the company lowered its full-year transthyretin revenue guidance after acknowledging that the early stages of the launch benefited from pent-up demand, particularly from patients who had stopped responding to tafamidis.The company reaffirmed its goal of delivering more than 25% total revenue compound annual growth rate through 2030, \"but our read is that the company sounded a bit more measured on that goal as they referred to it as an ambition more than a formal guide,\" the analysts said.The analysts said, overall, the update was disappointing, but the recent share price weakness appears \"overdone.\" The stock now trades at less than 2.5 times guided 2030 revenue, which still offers attractive upside if execution r","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4588":"碎股","GNMX":"Corgi Genomics & Precision Medicine ETF","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","PBE":"INVESCO BIOTECHNOLOGY & GENOME ETF","ALNY":"阿尔尼拉姆制药公司","BK4548":"巴美列捷福持仓","LU0882574055.USD":"富达全球健康医疗A ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4585":"ETF&股票定投概念"},"translate_title":"加拿大皇家银行表示，尽管季度疲软，但 Alnylam Pharmaceuticals 股价疲软看起来“过度”","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALNY":1.5,"GNMX":0.6,"PBE":0.6},"content_text":"Alnylam Pharmaceuticals (ALNY) share price weakness appears overdone despite a softer quarter, with Amvuttra growth and pipeline progress supporting upside, RBC Capital Markets said in a note emailed Friday.The analysts said Amvuttra revenue came in slightly below expectations, and the company lowered its full-year transthyretin revenue guidance after acknowledging that the early stages of the launch benefited from pent-up demand, particularly from patients who had stopped responding to tafamidis.The company reaffirmed its goal of delivering more than 25% total revenue compound annual growth rate through 2030, \"but our read is that the company sounded a bit more measured on that goal as they referred to it as an ambition more than a formal guide,\" the analysts said.The analysts said, overall, the update was disappointing, but the recent share price weakness appears \"overdone.\" The stock now trades at less than 2.5 times guided 2030 revenue, which still offers attractive upside if execution remains strong.RBC lowered its price target on Alnylam Pharmaceuticals from $445 to $350 and has an outperform rating on the stock.Price: 205.69, Change: +0.21, Percent Change: +0.10","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2655636030","isCrawlerRequest":true}